Joshua Linscott, MD

Articles by Joshua Linscott, MD

Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC

September 10th 2024

Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.

Joshua Linscott, MD, PhD, urologic oncology fellow, Moffitt Cancer Center

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

ByJoshua Linscott, MD

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

ByJoshua Linscott, MD

August 8th 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC

ByJoshua Linscott, MD

June 25th 2024

Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.

Joshua Linscott, MD

Articles by Joshua Linscott, MD

Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma